| 中文名稱 | 牙本質(zhì)磷蛋白/牙本質(zhì)骨唾液酸糖蛋白/牙本質(zhì)骨唾液酸磷蛋白抗體 |
| 別 名 | Dentin phosphophoryn; Dentin phosphoprotein; dentin phosphoryn; Dentin sialophosphoprotein; Dentin sialophosphoprotein precursor; Dentin sialoprotein; dentinogenesis imperfecta 1; DFNA39; DGI1; DMP3; DPP; DSP; DSPP_HUMAN; DTDP2. |
| 研究領(lǐng)域 | 細(xì)胞生物 免疫學(xué) 信號轉(zhuǎn)導(dǎo) 細(xì)胞周期蛋白 結(jié)合蛋白 細(xì)胞分化 細(xì)胞骨架 細(xì)胞外基質(zhì) |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:100-500 IHC-F=1:100-500 ICC=1:100-500 IF=1:100-500 （石蠟切片需做抗原修復(fù)） not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 47/129kDa |
| 細(xì)胞定位 | 細(xì)胞外基質(zhì) |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human Dentin sialoprotein:31-130/1301 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. |
| PubMed | PubMed |
| 產(chǎn)品介紹 | This gene encodes two principal proteins of the dentin extracellular matrix of the tooth. The preproprotein is secreted by odontoblasts and cleaved into dentin sialoprotein and dentin phosphoprotein. Dentin phosphoprotein is thought to be involved in the biomineralization process of dentin. Mutations in this gene have been associated with dentinogenesis imperfecta-1; in some individuals, dentinogenesis imperfecta occurs in combination with an autosomal dominant form of deafness. Allelic differences due to repeat polymorphisms have been found for this gene. [provided by RefSeq, Jul 2008] Function: DSP may be an important factor in dentinogenesis. DPP may bind high amount of calcium and facilitate initial mineralization of dentin matrix collagen as well as regulate the size and shape of the crystals. Subunit: Interacts with FBLN7. Subcellular Location: Secreted, extracellular space, extracellular matrix. Tissue Specificity: Expressed in teeth. DPP is synthesized by odontoblast and transiently expressed by pre-ameloblasts. Post-translational modifications: DSP is glycosylated. DISEASE: Defects in DSPP are the cause of deafness autosomal dominant type 39 with dentinogenesis imperfecta 1 (DFNA39/DGI1) [MIM:605594]. Affected individuals present DGI1 associated with early onset progressive sensorineural high-frequency hearing loss. Defects in DSPP are the cause of dentinogenesis imperfecta type 1 (DGI1) [MIM:125490]; also known as dentinogenesis imperfecta Shields type 2 (DGI2). DGI1 is an autosomal dominant disorder in which both the primary and the permanent teeth are affected. It occurs with an incidence of 1:8000 live births. The teeth are amber and opalescent, the pulp chamber being obliterated by abnormal dentin. The enamel, although unaffected, tends to fracture, which makes dentin undergo rapid attrition, leading to shortening of the teeth. Defects in DSPP are a cause of dentinogenesis imperfecta Shields type 3 (DGI3) [MIM:125500]. Patients with DGI3 do not have stigmata of osteogenesis imperfecta. The finding that a single defects in the DSPP gene causes both phenotypic patterns of DGI2 and DGI3 strongly supports the conclusion that these two disorders are not separate diseases but rather the phenotypic variation of a single genetic defect. Defects in DSPP are the cause of dentin dysplasia type 2 (DTDP2) [MIM:125420]; also known as dentin dysplasia Shields type 2. DTDP2 is an autosomal dominant disorder in which mineralization of the dentine of the primary teeth is abnormal. On the basis of the phenotypic overlap between, and shared chromosomal location with DGI2 it has been proposed that DTDP2 and DGI2 are allelic. From the results of recent studies, it is clear that different types of mutations in DSPP lead to the two different phenotypes. SWISS: Q9NZW4 Gene ID: 1834 Database links: Entrez Gene: 1834 Human Omim: 124585 Human SwissProt: Q9NZW4 Human Unigene: 678914 Human Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 產(chǎn)品圖片 |  Sample:Lane 1: Hela (Human) Cell Lysate at 30 ug Lane 2: SW480 (Human) Cell Lysate at 30 ug Lane 3: Du145 (Human) Cell Lysate at 30 ug Primary: Anti-DSPP (bs-10316R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 140 kD Observed band size: 130 kD Sample:Lane 1: Hela (Human) Cell Lysate at 30 ug Lane 2: SW480 (Human) Cell Lysate at 30 ug Lane 3: Du145 (Human) Cell Lysate at 30 ug Primary: Anti-DSPP (bs-10316R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 140 kD Observed band size: 130 kD  Sample:LOVO(Human) Cell Lysate at 30 ug 293T(Human) Cell Lysate at 30 ug Primary: Anti-DSPP (bs-10316R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size:140 kD Observed band size: 130 kD Sample:LOVO(Human) Cell Lysate at 30 ug 293T(Human) Cell Lysate at 30 ug Primary: Anti-DSPP (bs-10316R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size:140 kD Observed band size: 130 kD  Sample:EC-9706(Human) Cell Lysate at 30 ug MCF-7(Human) Cell Lysate at 30 ug Primary: Anti-DSPP (bs-10316R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 47/129 kD Observed band size: 129 kD Sample:EC-9706(Human) Cell Lysate at 30 ug MCF-7(Human) Cell Lysate at 30 ug Primary: Anti-DSPP (bs-10316R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 47/129 kD Observed band size: 129 kD  Tissue/cell: human laryngocarcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-DSPP Polyclonal Antibody, Unconjugated(bs-10316R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining Tissue/cell: human laryngocarcinoma; 4% Paraformaldehyde-fixed and paraffin-embedded;Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min; Incubation: Anti-DSPP Polyclonal Antibody, Unconjugated(bs-10316R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining |
我要詢價(jià)
*聯(lián)系方式：
(可以是QQ、MSN、電子郵箱、電話等，您的聯(lián)系方式不會被公開)
*內(nèi)容：
